Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Hospitalization 15% c19early.org/mf Mannucci et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with Type 2 Diabetes: A Retrospective Observational Study
Mannucci et al., Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, doi:10.2147/DMSO.S385646
Mannucci et al., Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with.., Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, doi:10.2147/DMSO.S385646
Oct 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 54,009 diabetes patients in Italy, showing lower mortality with metformin use.
risk of death, 38.0% lower, OR 0.62, p = 0.02, RR approximated with OR.
risk of hospitalization, 15.0% lower, OR 0.85, p = 0.25, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mannucci et al., 31 Oct 2022, retrospective, Italy, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 December, 2020.
Contact: gianpaolo.fadini@unipd.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress open access to scientific and medical research Diabetes, Metabolic Syndrome and Obesity For personal use only. Open Access Full Text Article ORIGINAL RESEARCH Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with Type 2 Diabetes: A Retrospective Observational Study Francesca Mannucci 1 , Giacomo Vitturi 2 , Luca Benacchio 3 , Luca Gino Sbrogiò 4 , Francesca Bano 1 , Annunziata Lapolla 5 , Francesco Piarulli 5 , Maria Cecilia Giron 2 , Angelo Avogaro 6 , Gian Paolo Fadini 6 1 Pharmaceutical Unit, Local Health Unit 6, Padua, Italy; 2Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy; 3Epidemiologic Unit, Local Health Unit 6, Padua, Italy; 4Prevention Department Local Health Unit 6, Padua, Italy; 5Diabetology Service, Local Health Unit 6, Padua, Italy; 6Department of Medicine, University of Padova, Padua, Italy Correspondence: Gian Paolo Fadini, Department of Medicine, University of Padova, Via Giustiniani 2, Padova, 35128, Italy, Tel +39 049 8214318, Fax +39 049 8212184, Email gianpaolo.fadini@unipd.it Purpose: Diabetes is a risk factor for COVID-19 severity, but the role played by glucose lowering medications (GLM) is still unclear. The aim of this study was to assess infection rates and outcomes of COVID-19 (hospitalization and mortality) in adults with diabetes assisted by the Local Health Unit of Padua (North-East Italy) according to the ongoing GLM. Patients and Methods: People with diabetes were identified using administrative claims, while those with SARS-CoV-2 infection were detected by cross referencing with the local COVID-19 surveillance registry. A multivariate logistic regression model was used to verify the association between GLM classes and the outcome. Results: SARS-CoV-2 infection rates were marginally but significantly higher in individuals with diabetes as compared to those without diabetes (RR 1.04, p = 0.043), though such relative 4% increase may be irrelevant from a clinical and epidemiological perspective. 1923 individuals with GLM-treated diabetes were diagnosed with COVID-19; 456 patients were hospitalized and 167 died. Those treated with insulin had a significantly higher risk of hospitalizations for COVID-19 (OR 1.48 p < 0.01) as were those treated with sulphonylureas/glinides (OR 1.34, p = 0.02). Insulin use was also significantly associated with higher mortality (OR 1.90, p < 0.01). Use of metformin was significantly associated with lower death rates (OR 0.62, p = 0.02). The association of other GLM classes with the outcome was not significant. Conclusion: Diabetes does not appear to modify the risk of SARS-CoV-2 infection in a clinically meaningful way, but strongly increases the rates of hospitalization and death. Insulin use was associated with worse outcomes, whereas metformin use was associated with lower mortality. Keywords: diabetes mellitus, SARS-CoV-2, antidiabetic drugs, metformin, hospitalization, odds ratio, administrative claims, Veneto
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit